Reduced Myocardial Flow in Heart Failure Patients With Preserved Ejection Fraction

被引:121
|
作者
Srivaratharajah, Kajenny [1 ]
Coutinho, Thais [1 ]
deKemp, Robert [1 ]
Liu, Peter [1 ]
Haddad, Haissam [1 ]
Stadnick, Ellamae [1 ]
Davies, Ross A. [1 ]
Chih, Sharon [1 ]
Dwivedi, Girish [1 ]
Guo, Ann [1 ]
Wells, George A. [1 ]
Bernick, Jordan [1 ]
Beanlands, Robert [1 ]
Mielniczuk, Lisa M. [1 ]
机构
[1] Univ Ottawa, Inst Heart, Div Cardiol, 40 Ruskin St, Ottawa, ON K1Y 4W7, Canada
关键词
comorbidity; coronary circulation; echocardiography; heart failure; positron emission tomography; POSITRON-EMISSION-TOMOGRAPHY; PROGNOSTIC VALUE; HOSPITAL ADMISSION; OLDER PATIENTS; BETA-BLOCKERS; DOUBLE-BLIND; BLOOD-FLOW; DYSFUNCTION; TRIAL; PERFUSION;
D O I
10.1161/CIRCHEARTFAILURE.115.002562
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-There remains limited insight into the pathophysiology and therapeutic advances directed at improving prognosis for patients with heart failure with preserved ejection fraction (HFpEF). Recent studies have suggested a role for coronary microvascular dysfunction in HFpEF. Rb-82 cardiac positron emission tomography imaging is a noninvasive, quantitative approach to measuring myocardial flow reserve (MFR), a surrogate marker for coronary vascular health. The aim of this study was to determine whether abnormalities exist in MFR in patients with HFpEF without epicardial coronary artery disease. Methods and Results-A total of 376 patients with ejection fraction >= 50%, no known history of obstructive coronary artery disease, and a confirmed diagnosis of heart failure (n=78) were compared with patients with no evidence of heart failure (n=298), further stratified into those with (n=186) and without (n=112) hypertension. Global and regional left ventricular MFR was calculated as stress/rest myocardial blood flow using Rb-82 positron emission tomography. Patients with HFpEF were more likely to be older, female, and have comorbid hypertension, diabetes mellitus, dyslipidemia, atrial fibrillation, anemia, and renal dysfunction. HFpEF was associated with a significant reduction in global MFR (2.16 +/- 0.69 in HFpEF versus 2.54 +/- 0.80 in hypertensive controls; P<0.02 and 2.89 +/- 0.70 in normotensive controls; P<0.001). A diagnosis of HFpEF was associated with 2.62 times greater unadjusted odds of having low global MFR (defined as <2.0) and remained a significant predictor of reduced global MFR after adjusting for comorbidities. Conclusions-HFpEF, in the absence of known history for obstructive epicardial coronary artery disease, is associated with reduced MFR independent of other risk factors.
引用
收藏
页数:16
相关论文
共 50 条
  • [11] Prognostic value of myocardial flow reserve in patients with heart failure with preserved ejection fraction
    Kopeva, K., V
    Maltseva, A. N.
    Grakova, E., V
    Mochula, A., V
    Soldatenko, M., V
    Kalyuzhin, V. V.
    Zavadovsky, K., V
    BYULLETEN SIBIRSKOY MEDITSINY, 2023, 22 (01): : 41 - 50
  • [12] DIFFUSE MYOCARDIAL FIBROSIS IS GREATLY ELEVATED IN MALES WITH HEART FAILURE WITH REDUCED EJECTION FRACTION, BUT NOT HEART FAILURE WITH PRESERVED EJECTION FRACTION
    Desai, Sanjal
    Haines, Philip
    Zamani, Payman
    Konda, Prasad
    Shiva-Kumar, Prithvi
    Peddireddy, Shivapriya
    Shekhar, Rahul Chandra
    Jain, Snigdha
    Kers, Scott
    Ferrari, Victor
    Chirinos, Julio
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (12) : A967 - A967
  • [13] Statins Beneficial for Heart Failure With Preserved Ejection Fraction But Not Heart Failure With Reduced Ejection Fraction?
    Ohte, Nobuyuki
    Little, William C.
    CIRCULATION JOURNAL, 2015, 79 (03) : 508 - 509
  • [14] Left Ventricular Longitudinal Myocardial Function of Heart Failure Patients With Transition From Reduced to Preserved Ejection Fraction and of Those With Preserved Ejection Fraction
    Nagai, Shun
    Nishimori, Makoto
    Kintsu, Masayuki
    Todo, Saki
    Ota, Eri
    Odajima, Susumu
    Takeuchi, Kimikazu
    Ichikawa, Yasushi
    Yamauchi, Yuki
    Shiraki, Hiroaki
    Yamashita, Kentaro
    Fukuda, Terunobu
    Hisamatsu, Eriko
    Hirata, Ken-ichi
    Tanaka, Hidekazu
    CIRCULATION REPORTS, 2024, 6 (05) : 161 - 167
  • [15] SERIAL CHANGE IN EJECTION FRACTION IN COMMUNITY HEART FAILURE PATIENTS WITH PRESERVED AND REDUCED EJECTION FRACTION
    Dunlay, Shannon
    Roger, Veronique L.
    Weston, Susan A.
    Redfield, Margaret M.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (14) : E398 - E398
  • [16] QTc INTERVAL IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION VS. HEART FAILURE WITH PRESERVED EJECTION FRACTION
    John, L. A.
    Christian, E. A.
    Harper, Y. I.
    Flatt, D. M.
    Heckle, M. R.
    Heard, B. Z.
    Jasper, J. B.
    Ramos, B. M.
    Weber, K. T.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2017, 65 (02) : 429 - 430
  • [17] Risk factors for heart failure rehospitalization in patients with preserved ejection fraction : Comparison between preserved ejection fraction and reduced ejection fraction
    Setoguchi, M.
    Hashimoto, Y.
    Isobe, M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2013, 12 : S282 - S282
  • [18] Prognostic Impact of Myocardial Fibrosis in Patients with Heart Failure - Comparison between Preserved and Reduced Ejection Fraction Heart Failure
    Aoki, Tatsuo
    Fukumoto, Yoshihiro
    Sugimura, Koichiro
    Satoh, Kimio
    Miura, Yutaka
    Nochioka, Kotaro
    Tatebe, Shunsuke
    Miyamichi-Yamamoto, Saori
    Nakayama, Masaharu
    Shimokawa, Hiroaki
    CIRCULATION, 2011, 124 (21)
  • [19] Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction
    Tromp, Jasper
    Khan, Mohsin A. F.
    Klip, IJsbrand T.
    Meyer, Sven
    de Boer, Rudolf A.
    Jaarsma, Tiny
    Hillege, Hans
    van Veldhuisen, Dirk J.
    van der Meer, Peter
    Voors, Adriaan A.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2017, 6 (04):
  • [20] Utilization of spironolactone in patients with reduced or preserved ejection fraction heart failure
    Adimadhyam, Sruthi
    Cosgrove, Austin
    Her, Qoua L.
    Lyons, Jennifer
    Eworuke, Efe
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 229 - 230